Specialty Pharmacy

Inhibiting the protein PARP 14 shows promise in stopping uncontrolled cancer cell growth.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses significant challenges in over the next five years in specialty pharmacy.

Research may lead to targeted therapies with reduced side effects.

Cladribine was previously denied market authorization on the suspicion that it may cause cancer.

Patients should be closely monitored by proper diagnostic methods.

The FDA has accepted Sandoz's Biologics License Application (BLA) for its proposed etanercept (Enbrel) biosimilar.

Study finds inhibition of the NOTCH4 signal may be a promising target to prevent the growth and spread of cancer.

Novel method may reduce the length of treatment time and decrease side effects.

Arava can reduce RA symptoms and slow down associated structural damage.

Keytruda treats patients with metastatic non-small cell lung cancer whose disease has progressed despite other treatment methods.

Guidelines include risk classification system to remind caregivers to examine diabetics' feet.

Therapy with binimetinib and ribociclib shows significant clinical activity in NRAS-mutant melanoma patients.

The latest stabbing of a pharmacist has renewed calls for tougher sentencing and increased policing to protect pharmacists.

Medication dispensing within the first few months of prescribing chronic therapy can precisely predict future patient adherence.

Viral induction greater than any other latency reversing agent.

Top cancer-related news from the past week.

New guidelines based on overwhelming clinical evidence that ART is effective.

Economic development and urbanization factors influence cancer incidence growth.

Around 11% of patients who use insulin have adverse drug reactions.

A pharmacist in Nebraska has pleaded guilty to what is possibly the largest case of Medicaid fraud in the state.

Hepatitis C infections are more likely to become persistent and to lead to progressive liver disease in patients with HIV.

Chronic inflammatory skin condition associated with decreased quality of life and increased all-cause mortality.

New therapeutic target may decrease breast cancer risk.

Top stories of the week on Specialty Pharmacy Times.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how accountable care organizations impact specialty pharmacy.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.